Nasdaq

Jasper: First patient dosed in ETESIAN clinical study of briquilimab in asthma

Jasper Therapeutics (JSPR), announced that the first patient has been dosed in Jasper’s Phase 1b/2a clinical challenge study evaluating briquilimab in allergic asthma, called ETESIAN,Evaluating The ...
Enid News & Eagle

Jasper Therapeutics Announces First Patient Dosed in Phase 1b/2a ETESIAN Clinical Study of ...

“Dosing of the first patient in our ETESIAN study in asthma is a significant milestone, marking our third clinical program evaluating briquilimab in an inflammatory disease driven by unwanted mast ...
Nasdaq

Jasper Therapeutics Reports Promising BEACON Study Results for Briquilimab in Chronic Spontaneous Urticaria Amid Drug Product Lot Investigation

Jasper Therapeutics, Inc. announced promising results from its BEACON Phase 1b/2a study of briquilimab, an antibody therapy targeting mast cell diseases like chronic spontaneous urticaria (CSU). In ...
TipRanks on MSN

Jasper Therapeutics Advances Briquilimab Study for Chronic Urticaria

Jasper Therapeutics, Inc. (($JSPR)) announced an update on their ongoing clinical study. Jasper Therapeutics, Inc. is conducting a clinical study ...
Seeking Alpha

Jasper Therapeutics Announces Oral Presentation of Positive Final Results from Phase 1 Study of Briquilimab in Patients with AML or MDS Undergoing Hematopoietic Cell Transplant ...

REDWOOD CITY, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (JSPR) (Jasper), a biotechnology company focused on the development of briquilimab, a novel antibody therapy targeting ...